You are here

  • Home
  • Archive
  • Volume 82, Issue 12
  • Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3)

Article metrics

Article menu
Rheumatoid arthritis
Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3)

 

Online download statistics by month:

Online download statistics by month: September 2023 to April 2025

AbstractFullPdf
Sep 202311571114336
Oct 2023581577172
Nov 202313431326257
Dec 2023683673229
Jan 2024305287163
Feb 2024363344125
Mar 2024371368133
Apr 2024345338137
May 2024336335115
Jun 2024181173103
Jul 202432934189
Aug 202424624280
Sep 202422121898
Oct 2024283281140
Nov 2024271260130
Dec 202426526283
Jan 202517417965
Feb 202514614769
Mar 202512512643
Apr 202510110033
Total782676912600